CVRx (NASDAQ:CVRX – Get Free Report) and Sanuwave Health (NASDAQ:SNWV – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.
Institutional and Insider Ownership
75.3% of CVRx shares are owned by institutional investors. Comparatively, 42.5% of Sanuwave Health shares are owned by institutional investors. 16.6% of CVRx shares are owned by insiders. Comparatively, 14.4% of Sanuwave Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares CVRx and Sanuwave Health”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CVRx | $61.19 million | 0.61 | -$53.31 million | ($1.98) | -0.70 |
| Sanuwave Health | $44.02 million | 1.01 | $11.81 million | $0.24 | 21.54 |
Sanuwave Health has lower revenue, but higher earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
CVRx has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Sanuwave Health has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.
Profitability
This table compares CVRx and Sanuwave Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CVRx | -84.93% | -152.35% | -50.93% |
| Sanuwave Health | 32.38% | 1,728.10% | 39.04% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for CVRx and Sanuwave Health, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CVRx | 1 | 3 | 2 | 0 | 2.17 |
| Sanuwave Health | 2 | 0 | 1 | 0 | 1.67 |
CVRx currently has a consensus price target of $4.30, suggesting a potential upside of 209.35%. Sanuwave Health has a consensus price target of $47.00, suggesting a potential upside of 809.09%. Given Sanuwave Health’s higher probable upside, analysts clearly believe Sanuwave Health is more favorable than CVRx.
Summary
Sanuwave Health beats CVRx on 9 of the 14 factors compared between the two stocks.
About CVRx
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
About Sanuwave Health
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company’s lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body’s normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.
